You are here

Article Text

Article menu
Download PDFPDF
DTB Select
MHRA Drug Safety Update: denosumab (Xgeva) and rebound hypercalcaemia

Abstract

Review of: Medical and Healthcare products Regulatory Agency. Denosumab for giant cell tumor of bone: risk of clinically significant hypercalcaemia following discontinuation. Drug Safety Update 2018;11(11);2.

https://doi.org/10.1136/dtb.2018.11.000040

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Provenance and peer review Internally peer reviewed.

    • Contributors DTB Team.